The Medicines Company Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible S Jan 6, 2020 01:12PM
Novartis completes tender offer for all outstanding shares of The Medicines Company Jan 6, 2020 01:00AM
Novartis tender offer for The Medicines Company commences Dec 5, 2019 01:00AM
Medicines Co. (MDCO) Agrees to be Acquired by Novartis AG (NVS) for $9.7B, or $85/Share Nov 24, 2019 04:42PM
The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion Nov 24, 2019 03:05PM


Nov 24, 2019 03:00PM Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
Nov 18, 2019 09:02AM Medicines Co. (MDCO) Company Announces ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing
Nov 18, 2019 09:00AM The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing
Nov 16, 2019 10:45AM The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
Nov 6, 2019 04:30PM The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019
Oct 30, 2019 07:00AM The Medicines Company Reports Third-Quarter 2019 Financial Results and Achievement of Major Milestones for Inclisiran
Oct 24, 2019 04:30PM The Medicines Company to Announce Third Quarter 2019 Financial Results on October 30
Oct 4, 2019 11:00AM The Medicines Company to Participate in the Chardan 3rd Annual Genetic Medicines Conference
Sep 25, 2019 07:06AM Medicines Co. (MDCO) Reports Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD
Sep 25, 2019 07:05AM The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients
Sep 25, 2019 07:01AM Medicines Co. (MDCO) ORION-9 Phase 3 Study of Inclisiran in HeFH Met all Primary and Secondary Endpoints
Sep 25, 2019 07:00AM The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients
Sep 3, 2019 05:54AM Medicines Co. (MDCO) Highlights Results from ORION-11, First Ph. 3 Trial of Inclisiran, Showing Durable & Potent Lowering of LDL-C with Twice-Yearly Dosing
Sep 2, 2019 02:30AM The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
Aug 26, 2019 07:03AM Medicines Co. (MDCO) Reports Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran
Aug 26, 2019 07:00AM The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran
Jul 24, 2019 07:00AM The Medicines Company Reports Second-Quarter 2019 Financial Results and Updates Clinical Development Program
Jul 17, 2019 07:00AM The Medicines Company to Announce Second Quarter 2019 Financial Results on July 24
May 27, 2019 10:21AM The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress
May 20, 2019 08:39AM Medicines Co. (MDCO) Announces New L-T Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol (Earlier)
May 18, 2019 04:50PM New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years
May 10, 2019 07:00AM The Medicines Company to Host Investor Conference Call and Webcast During National Lipid Association’s 2019 Scientific Sessions
May 7, 2019 07:00AM The Medicines Company to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference
Apr 25, 2019 07:00AM The Medicines Company Reports First-Quarter 2019 Financial Results and Significant Progress with the Inclisiran Clinical Development Program
Apr 18, 2019 07:00AM The Medicines Company to Announce First Quarter 2019 Financial Results on April 25
Feb 27, 2019 07:00AM The Medicines Company Reports Fourth-Quarter and Full Year 2018 Business and Financial Results
Feb 21, 2019 07:00AM The Medicines Company Announces Upcoming Investor Conference Presentations
Feb 20, 2019 07:00AM The Medicines Company to Announce Fourth-Quarter and Full-Year 2018 Financial Results on February 27
Nov 14, 2018 04:09PM Einhorn's Greenlight Capital Enters Michael Kors (KORS), Seadrill (SDRL); Cuts GM (GM), Liquidates Apple (AAPL)
Aug 14, 2018 07:52AM Einhorn's Greenlight Capital Shows Lowered Stake in Apple (AAPL), GM (GM), Micron (MU) (more....)
May 15, 2018 04:09PM Einhorn's Greenlight Capital Enters Office Depot (ODP), Abercrombie & Fitch (ANF) (more...) - 13F
Feb 14, 2018 04:19PM Einhorn's Greenlight Capital Enters Michael Kors (KORS), JP Penney (JCP), Under Armour (more...)
Dec 14, 2017 07:01AM Matinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors
Nov 6, 2017 07:16AM Medicines Co. (MDCO), Alnylam Pharmaceuticals (ALNY) Announce Initiation of Phase III Clinical Trials of Inclisiran
Nov 6, 2017 07:00AM The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran
Oct 17, 2017 07:30AM Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors
Aug 28, 2017 07:04AM Medicines Co. (MDCO), Alnylam (ALNY) Announces New, Positive Data from ORION-1 Phase II Study of Inclisiran
Aug 28, 2017 07:00AM New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials
Apr 26, 2017 07:05AM Medicines Company (MDCO), Alnylam (ALNY) Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
Apr 26, 2017 07:00AM The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
Nov 14, 2016 09:24AM Pre-Open Stock Movers 11/14: (CRBP) (HAR) (DGII) (MENT) Higher; (DVAX) (HEAR) (ACM) Lower (more...)
Oct 6, 2016 09:22AM Pre-Open Stock Movers 10/06: (ALQA) (SCYX) (ZUMZ) Higher; (ALNY) (TWTR) (MDCO) Lower (more...)
Aug 31, 2015 05:20PM Market Wrap: Crude Staves-Off Loss for August; Apple, Cisco Enter Partnership; Twitter Gains on Upgrade
Aug 31, 2015 09:25AM Pre-Open Stock Movers 08/31: (VTL) (MDCO) (TWTR) Higher; (ARIA) (AUY) (UTX) Lower (more...)
Aug 7, 2015 10:00AM The Medicines Company (Nasdaq: MDCO) to Ring The Nasdaq Stock Market Opening Bell
Aug 7, 2015 10:00AM The Medicines Company (Nasdaq: MDCO) to Ring The Nasdaq Stock Market Opening Bell
Jul 2, 2015 12:12PM Streetinsider.com's Hot Lunchtime Reads 7/2: (VRTX) (TWTR) (AMD) (MDCO) (AMBA)
Oct 28, 2014 09:33AM Pre-Open Stock Movers 10/28: (RCPT) (TRNX) (VDSI) (MSG) Higher; (TWTR) (AMKR) (CVLT) Lower (more...)
Oct 27, 2014 06:22PM After-Hours Stock Movers 10/27: (TRNX) (RCPT) (SANM) Higher; (AKMR) (TWTR) (KSS) Lower (more...)